# Cardiovascular Disease and Lipoprotein(a) FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/cardiovascular-disease-and-lipoprotein-a

> 2 upcoming FDA catalysts in cardiovascular Disease and Lipoprotein(a): pelacarsen (tqj230, NVS) on Jan to Apr 2030 (topline data readout); pelacarsen (tqj230, NVS) on January 2030 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| July 16, 2026 | [TQJ230 primary completion](https://sec-api.dev/pdufa/tqj230) | NVS | Cardiovascular Disease and Lipoprotein(a) | completed | "NCT04023552 (Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-07-16 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04023552)) |
| Jan to Apr 2030 | [Pelacarsen (tqj230) topline data readout](https://sec-api.dev/pdufa/pelacarsen-tqj230) | NVS | Cardiovascular Disease and Lipoprotein(a) | scheduled | "NCT07517263 (An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2030-01-09 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07517263)) |
| January 2030 | [Pelacarsen (tqj230) primary completion](https://sec-api.dev/pdufa/pelacarsen-tqj230) | NVS | Cardiovascular Disease and Lipoprotein(a) | scheduled | "NCT07517263 (An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2030-01-09 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07517263)) |

## Drugs

- [TQJ230](https://sec-api.dev/pdufa/tqj230) (NVS)
- [Pelacarsen (tqj230)](https://sec-api.dev/pdufa/pelacarsen-tqj230) (NVS)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/cardiovascular-disease-and-lipoprotein-a.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Cardiovascular Disease and Lipoprotein(a) FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/cardiovascular-disease-and-lipoprotein-a

```bibtex
@misc{secapidev_indications_cardiovascular_disease_and_lipoprotein_a_20261116,
  title        = {Cardiovascular Disease and Lipoprotein(a) FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/cardiovascular-disease-and-lipoprotein-a}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_cardiovascular_disease_and_lipoprotein_a_20261116","title":"Cardiovascular Disease and Lipoprotein(a) FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/cardiovascular-disease-and-lipoprotein-a","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
